PROCESS FOR LESSENING POLYMORPHIC CONVERSION OF A DRUG
Kind Code:
A2
Abstract not available for EP1216058
Abstract of corresponding document: WO0121211
The present invention is directed to maintaining a therapeutic agent comprising a drug in its preferred polymorphic form for providing an indicated therapy. The therapeutic agent is maintained in the polymorphic form by blending a polymer with the therapeutic agent which lessens the conversion of the therapeutic agent from the desired form to a different, undesired form.
Abstract of corresponding document: WO0121211
The present invention is directed to maintaining a therapeutic agent comprising a drug in its preferred polymorphic form for providing an indicated therapy. The therapeutic agent is maintained in the polymorphic form by blending a polymer with the therapeutic agent which lessens the conversion of the therapeutic agent from the desired form to a different, undesired form.
Inventors:
Shivanand, Padmaja (US)
Ayer, Atul D. (US)
Marks, Susan M. (US)
Ayer, Atul D. (US)
Marks, Susan M. (US)
Application Number:
EP20000973370
Publication Date:
06/26/2002
Filing Date:
09/19/2000
View Patent Images:
Export Citation:
Assignee:
ALZA CORP (US)
International Classes:
A61K9/14; A61K9/14; A61K9/00; A61K9/00; A61K9/16; A61K9/16; A61K9/20; A61K9/20; A61K9/48; A61K9/48; A61K47/02; A61K47/04; A61K47/12; A61K47/12; A61K47/16; A61K47/18; A61K47/24; A61K47/24; A61K47/30; A61K47/30; A61K47/32; A61K47/32; A61K47/34; A61K47/34; A61K47/36; A61K47/36; A61K47/38; A61K47/38; A61K47/40; A61K47/40; A61K47/44; A61K47/44; (IPC1-7): A61K47/30; A61K9/16
European Classes:
A61K9/00L4; A61K9/16H6B; A61K9/16H6D; A61K9/16H6F; A61K9/16H6H; A61K9/20H6B; A61K9/20H6D; A61K9/20H6F; A61K9/20H6H
Other References:
See references of WO 0121211A2